آشنایی با ISI Web of Science





ISI Web of

KNOWLEDGE

Transforming Research




The New Face of Research








... the ISI Web of KNOWLEDGE



پیشینه

- موسسه اطلاعات علمي Institute of scientific آمریکا ۱۹۵۰ در دهه ۱۹۵۰ توسط یوجین گارفیلد پایه گذاری شد و فکر تدوین یك نمایه نامه استنادی از سال ۱۹۵۰ توسط وی مطرح شد
- هدف از تاسیس این موسسه و تهیه نمایه نامه استنادی , کمك به بازیابی اطلاعات چاپ شده علمی با استفاده از روش استنادی است.



چرا نمایه نامه استنادی علوم؟

- مرسوم است که پژوهشگران در نوشته های علمی و تحقیقاتی خویش به آثاری استناد کنند که در ارتباط با موضوع آنها نوشته شده و از این آثار در تایید نظرات خویش استفاده کنند یا تعارضات آنها را با اندیشه های علمی روز یا یافته های جدید نشان دهند
- به این نوشته ها که مورد استفاده پژوهشگر قرار گرفته , اثر استناد شده cited item و نوشته خود پژوهشگر که به آن اثر استناد نموده , اثر استناد Citing item کننده
- چنانچه مشخصات آثار استناد شده و مقاله های استناد کننده به آنها در یک مجموعه جمع شوند , نمایه استنادی بوجود می آید که نمایه استنادی علوم
 پا SCI یا web of science نمونه بارز و جامع آن است .

اهداف و کاربردها


- یک مقاله توسط چه کسانی و در کدام منابع مورد استناد قرار گرفته است ؟
- یک اثر تحقیقی یا یک روش علمی مورد استفاده یا انتقاد دیگران قرار گرفته است ؟
 - چه کسانی بر روی یک موضوع خاص مشغول تحقیق هستند؟
- آیا موضوع یا روش خاصی هنوز مورد پژوهش یا کاربرد پژوهشگران جهان است ؟
 - چه زمینه های موضوعی در هر سال بیشتر مورد توجه بوده است ؟
 - میزان اطلاعات علمی منتشر شده در یک کشور خاص چگونه است ؟
- ارزش جهانی مقالات یک پژوهشگر از نطر کیفی چگونه است؟(اچ ایندکس)


Use the Web of Science tab for:


- Cited Reference Searching
- Author Finder
- Address Searching
- · Sorting results by Times Cited
- · Citation Reports (h-index)

کاربردهای web of science در محیط وب:

- •جستجوی مآخذ و استنادها
- •جستجوی نویسندگان و پژوهشگران
- •جستجوی سازمان های علمی و پژوهشی
- •تنظیم نتایج بر اساس تعداد دفعات استناد
- •گزارش های تحلیلی استنادی (اچ ایندکس)







Please give us your feedback on using ISI Web of Knowledge.

Discover Web of Science

Medical Sciences

Explore top high-impact journals with powerful tools such as cited reference searching and Author Finder. 256 categories thoroughly cover the sciences, social sciences, arts, and humanities,

More information

- Want to know more?
- Training in multiple languages

Customize Your Experience

Sign In | Register

- Save and manage your references online with EndNote Web - freely available and fully integrated.
- Save and run searches
- Create alerts and RSS feeds
- Choose your start page
- Want to know more?

My ResearcherID

- What is ResearcherID?
- Sign In to ISI Web of Knowledge to get your ResearcherID.

Further Information

- What's New?
- Training and Support
- Help Desk
- Provide Feedback
- Search the Web with Thomson Scientific WebPlus



Web of Science

Additional Resources

Mashad University of Medical Sciences

Web Search Tools:

Thomson Scientific WebPlus

Find scientifically relevant Web content fast! Search the open Web and quickly see the most relevant content for the topics you care about, with Thomson Scientific WebPlus.

Web Sites:

ISI HighlyCited.comSM

This free, expert gateway uses citation data to deliver comprehensive information about the most significant scientists and scholars publishing today.

BiologyBrowser

A free database of resources and links for the life sciences information community.

Index to Organism Names

The world's largest online database of scientific organism names

in-cites

A free, behind-the-scenes look at key scientists, journals, institutions, nations, and papers selected by Essential Science Indicators; includes interviews, first-person essays, and profiles.

ResearcherID.com

ResearcherID provides the global research community with an invaluable index to author information. Each author listed is assigned a unique number, which serves as a fast, easy identifier

Science Watch®

Track hot or emerging fields as well as national and international trends in basic research with this bimonthly newsletter.

Special Topics®

Free citation analyses and commentary about today's most notable scientific research areas. Features interviews. essays and profiles of prominent scientists, institutions, and journals.

Thomson Scientific


Find out more about information-based solutions available to the academic, business, and R&D communities.

How can I use these resources?

These products and Web sites provide a variety of data and analysis relevant to research.

Read help for more information.





More information Mashad University of Medical Sciences

Discover Web of Science

Explore top high-impact journals with powerful tools such as cited reference searching and Author Finder, 256 categories thoroughly cover the sciences, social sciences, arts, and humanities,

- Want to know more?
- Training in multiple languages

Customize Your Experience

Sign In | Register

- Save and manage your references online with EndNote Web - freely available and fully integrated.
- Save and run searches
- Create alerts and RSS feeds
- Choose your start page
- Want to know more?

My ResearcherID


- What is ResearcherID?
- Sign In to ISI Web of Knowledge to get your ResearcherID.


Further Information

- What's New?
- Training and Support
- Help Desk
- Provide Feedback
- Search the Web with Thomson Scientific WebPlus



100%





More information Mashad University of Medical Sciences

Discover Web of Science

Explore top high-impact journals with powerful tools such as cited reference searching and Author Finder, 256 categories thoroughly cover the sciences, social sciences, arts, and humanities,

- Want to know more?
- Training in multiple languages

Customize Your Experience

Sign In | Register

- Save and manage your references online with EndNote Web - freely available and fully integrated.
- Save and run searches
- Create alerts and RSS feeds
- Choose your start page
- Want to know more?

My ResearcherID

- What is ResearcherID?
- Sign In to ISI Web of Knowledge to get your ResearcherID.

Further Information


- What's New?
- Training and Support
- Help Desk
- Provide Feedback
- Search the Web with Thomson Scientific WebPlus



100%

LETTER (16) more options / values Authors	5. Title: Cytomegalovirus disease in HIV-1 infected Chilean children Author(s): Pena A, Larranaga C, Luchsinger V, et al. Source: REVISTA CHILENA DE INFECTOLOGIA Volume: 24 Issue: 6 Pages: 477-484 Published: DEC 2007 Times Cited: 0								
➤ Source Titles ➤ Publication Years	6. Title: Children's views on their involvement in clinical research Author(s): Chappuy H, Doz F, Blanche S, et al. Source: PEDIATRIC BLOOD & CANCER Volume: 50 Issue: 5 Pages: 1043-1046 Published: MAY 2008 Times Cited: 0								
► Languages ► Countries/Territories For advanced refine options, use	7. Title: Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus Author(s): Purdy JB, Gafni RI, Reynolds JC, et al. Source: JOURNAL OF PEDIATRICS Volume: 152 Issue: 4 Pages: 582-584 Published: APR 2008 Times Cited: 0								
■ Analyze Results	8. Title: Do-not-resuscitate orders and/or hospice care, psychological health, and quality of life among children/adolescents with acquired immune deficiency syndrome Author(s): Lyon ME, Williams PL, Woods ER, et al. Source: JOURNAL OF PALLIATIVE MEDICINE Volume: 11 Issue: 3 Pages: 459-469 Published: APR 2008 Times Cited: 1								
	 Title: Assisted reproductive techniques in the context of HIV: the infectiologist's point of view Author(s): Tubiana R Source: GYNECOLOGIE OBSTETRIQUE & FERTILITE Volume: 35 Issue: 10 Pages: 1030-1034 Published: OCT 2007 Times Cited: 0 								
	10. Title: Challenges in implementing CD4 testing in resource-limited settings Author(s): Peter T, Badrichani A, Wu E, et al. Source: CYTOMETRY PART B-CLINICAL CYTOMETRY Volume: 74B Pages: \$123-\$130 Supplement: Suppl. 1 Published: 2008 Times Cited: 0								
Results: 1634 Show 10 per page 🕶	Page 1 of 164 Go ►► Sort by: Latest Date								
Output Records Step 1: Selected Records on page All records on page Records to	Step 2: O Authors, Title, Source □ plus Abstract Full Record □ plus Cited Reference Step 3: [How do I export to bibliographic management software?] Print E-mail Add to Marked List Save to EndNote Web Save to EndNote, RefMan, ProCite Save to other Reference Software Save								
1634 records matched your query of the 177 Key: 🎮 = Structure available.	731978 in the data limits you selected.								





	<u>and the state of </u>					
Web of Science Additi	ional Resources					
Search Cited Reference Search	Structure Search Advanced Search Search History Marked List (0)					
Web of Science®						
Results Topic=(hiv children to Timespan=All Years, Datab	reatment) bases=SCI-EXPANDED, IC, CCR-EXPANDED [back to 1840]. Thomson Scientific WebPlus View Web Results >>					
Results: 1634	Page 1 of 164 Go ►► Sort by: Times Cited ►►					
Refine Results	Print E-mail Add to Marked List Save to EndNote Web more options Analyze Results III Create Citation Report					
Search within results for Search Subject Areas Refine	1. Title: REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE- 1 WITH ZIDOVUDINE TREATMENT Author(s): CONNOR EM, SPERLING RS, GELBER R, et al. Source: NEW ENGLAND JOURNAL OF MEDICINE Volume: 331 Issue: 18 Pages: 1173-1180 Published: NOV 3					
INFECTIOUS DISEASES (508) PEDIATRICS (432)	1994 Times Cited: 1,773					
☐ IMMUNOLOGY (410) ☐ MEDICINE, GENERAL & INTERNAL (195) ☐ VIROLOGY (181)	2. Title: Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients Author(s): Lennette ET, Blackbourn DJ, Levy JA Source: LANCET Volume: 348 Issue: 9031 Pages: 858-861 Published: SEP 28 1996 Times Cited: 387					
more options / values ▼ Document Types Refine □ ARTICLE (1,356) □ REVIEW (190) □ EDITORIAL MATERIAL (29)	□ 3. Title: 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial Author(s): Dabis F, Msellati P, Meda N, et al. Source: LANCET Volume: 353 Issue: 9155 Pages: 786-792 Published: MAR 6 1999 Times Cited: 287					
MEETING ABSTRACT (21) LETTER (18) more options / values	4. Title: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues Author(s): Blanche S, Tardieu M, Rustin P, et al. Source: LANCET Volume: 354 Issue: 9184 Pages: 1084-1089 Published: SEP 25 1999 Times Cited: 269					
 Authors Source Titles Publication Years 	5. Title: Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 Author(s): Ormerod P, Campbell I, Novelli V, et al. Source: THORAX Volume: 53 Issue: 7 Pages: 536-548 Published: JUL 1998 Times Cited: 232					

Take the next step 🧷

Additional Resources

Search Cited Reference Search Structure Search Advanced Search Marked List (0) Search History

Web of Science®

Web of Science

<< Back to results list

Record 1 of 1634

Record from Web of Science®

REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT

Print (E-mail) (Add to Marked List) (Save to EndNote Web

Author(s): CONNOR EM, SPERLING RS, GELBER R, KISELEV P, SCOTT G, OSULLIVAN MJ, VANDYKE R, BEY M, SHEARER W, JACOBSON RL, JIMENEZ E, ONEILL E, BAZIN B, DELFRAISSY JF, CULNANE M, COOMBS R, ELKINS M, MOYE J, STRATTON P, BALSLEYJ

Source: NEW ENGLAND JOURNAL OF MEDICINE Volume: 331 Issue: 18 Pages: 1173-1180 Published: NOV 3

Times Cited: 1.773 References: 39

Abstract: Background and Methods. Maternal-infant transmission is the primary means by which young children become infected with human immunodeficiency virus type 1 (HIV). We conducted a randomized, double-blind, placebo-controlled trial of the efficacy and safety of zidovudine in reducing the risk of maternal-infant HIV transmission. HIV-infected pregnant women (14 to 34 weeks' gestation) with CD4+ T-lymphocyte counts above 200 cells per cubic millimeter who had not received antiretroviral therapy during the current pregnancy were enrolled. The zidovudine regimen included antepartum zidovudine (100 mg orally five times daily), intrapartum zidovudine (2 mg per kilogram of body weight given intravenously over a one-hour period, then 1 mg per kilogram per hour until delivery), and zidovudine for the newborn (2 mg per kilogram orally every six hours for six weeks). Infants with at least one positive HIV culture of peripheral-blood mononuclear cells were classified as HIV-infected.

Results, From April 1991 through December 20, 1993, the cutoff date for the first interim analysis of efficacy, 477 pregnant women were enrolled; during the study period, 409 gave birth to 415 live-born infants. HIV-infection status was known for 363 births (180 in the zidovudine group and 183 in the placebo group). Thirteen infants in the zidovudine group and 40 in the placebo group were HIV-infected. The proportions infected at 18 months, as estimated by the Kaplan-Meier method, were 8.3 percent (95 percent confidence interval, 3.9 to 12.8 percent) in the zidovudine group and 25.5 percent (95 percent confidence interval, 18.4 to 32.5 percent) in the placebo group. This corresponds to a 67.5 percent (95 percent confidence interval, 40.7 to 82.1 percent) relative reduction in the risk of HIV transmission (Z = 4.03, P = 0.00006). Minimal short-term toxic effects were observed. The level of hemoglobin at birth in the infants in the zidovudine group was significantly lower than that in the infants in the placebo group. By 12 weeks of age, hemoglobin values in the two groups were similar.

Conclusions. In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six Cited by: 1773

This article has been cited 1773 times (from Web of Science).

Ana CP, Ana MAP, Elba WH, et al. Changes in vertically transmitted human immunodeficiency virus infection Chile REVISTA CHILENA DE INFECTOLOGIA 5 368-371 OCT

Robinson JL Testing for HIV infection in pregnancy PAEDIATRICS & CHILD HEALTH 3 221-224 MAR

de Almeida CAF, Benatti MCC Occupational exposure of health care workers to organic fluids and adhesion to chemoprophylaxis REVISTA DA ESCOLA DE ENFERMAGEM DA USP 1 120-126 MAR

view all 1773 citing articles]

Create Citation Alert

Related Records:

Find similar records based on shared references (from Web of Science).

[view related records]



Internet

Find similar records based on shared references (from Web of Science). Conclusions. In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six [view related records] weeks reduced the risk of maternal-infant HIV transmission by approximately two thirds. Document Type: Article References: 39 Language: English View the bibliography of this record (from Web of Science). KeyWords Plus: CLINICAL-TRIALS GROUP; RETROVIRAL DISEASE; HIV-1 INFECTION; PREGNANCY; VIREMIA; EMBRYOS; THERAPY; 3'-AZIDO-3'-DEOXYTHYMIDINE; PHARMACOKINETICS; PREIMPLANTATION Suggest a correction Addresses: UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT PEDIAT, NEWARK, NJ 07103 USA If you would like to improve the CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA quality of this product by HARVARD UNIV, SCH PUBL HLTH, AIDS CLIN TRIALS GRP, CTR STAT & DATA ANAL, BOSTON, MA 02115 USA suggesting corrections, please fill DANA FARBER CANC INST, BOSTON, MA USA out this form. UNIV MIAMI, SCH MED, DEPT PEDIAT, MIAMI, FL USA UNIV MIAMI, SCH MED, DEPT OBSTET & GYNECOL, MIAMI, FL 33101 USA TULANE UNIV. SCH MED. DEPT PEDIAT. NEW ORLEANS, LA 70112 USA LOUISIANA STATE UNIV, SCH MED, DEPT OBSTET & GYNECOL, NEW ORLEANS, LA USA BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA UNIV TEXAS, SCH MED, DEPT OBSTET & GYNECOL, HOUSTON, TX USA SAN JUAN CITY HOSP, DEPT PEDIAT, SAN JUAN, PR USA SAN JUAN CITY HOSP, DEPT OBSTET & GYNECOL, SAN JUAN, PR USA AGENCE NATL RECH SIDA, PARIS, FRANCE UNIV WASHINGTON, SCH MED, SEATTLE, WA USA BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA NICHHD, BETHESDA, MD USA NIAID, DIV AIDS, PEDIAT MED BRANCH, BETHESDA, MD 20892 USA Publisher: MASS MEDICAL SOC, 10 SHATTUCK, BOSTON, MA 02115 Subject Category: Medicine, General & Internal IDS Number: PN806 ISSN: 0028-4793 ■ Record 1 of 1634 ▶ << Back to results list Record from Web of Science® **Output Record** Step 1: Step 2: [How do I export to bibliographic management software?] (Print) (E-mail) (Add to Marked List) (Save to EndNote Web) (Save to EndNote), RefMan, ProCite) Authors, Title, Source plus Abstract Save to other Reference Software V Save Full Record plus Cited Reference

Internet

₫ 100% 🔻

Take the next step 🧷

Web of Science

Additional Resources

Advanced Search

Search Cited Reference Search

Structure Search

Search History

Marked List (0)

Web of Science®

<< Back to results list

Record 1 of 1634

Record from Web of Science®

REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT

Print (E-mail) (Add to Marked List) (Save to EndNote Web

Author(s): CONNOR EM, SPERLING RS, GELBER R, KISELEV P, SCOTT G, OSULLIVAN MJ, VANDYKE R, BEY M, SHEARER W, JACOBSON RL, JIMENEZ E, ONEILL E, BAZIN B, DELFRAISSY JF, CULNANE M, COOMBS R, ELKINS M, MOYE J, STRATTON P, BALSLEY J

Source: NEW ENGLAND JOURNAL OF MEDICINE Volume: 331 Issue: 18 Pages: 1173-1180 Published: NOV 3 1994

Times Cited: 1.773 References: 39

Abstract: Background and Methods. Maternal-infant transmission is the primary means by which young children become infected with human immunodeficiency virus type 1 (HIV). We conducted a randomized, double-blind, placebo-controlled trial of the efficacy and safety of zidovudine in reducing the risk of maternal-infant HIV transmission. HIV-infected pregnant women (14 to 34 weeks' gestation) with CD4+ T-lymphocyte counts above 200 cells per cubic millimeter who had not received antiretroviral therapy during the current pregnancy were enrolled. The zidovudine regimen included antepartum zidovudine (100 mg orally five times daily), intrapartum zidovudine (2 mg per kilogram of body weight given intravenously over a one-hour period, then 1 mg per kilogram per hour until delivery), and zidovudine for the newborn (2 mg per kilogram orally every six hours for six weeks). Infants with at least one positive HIV culture of peripheral-blood mononuclear cells were classified as HIV-infected.

Results, From April 1991 through December 20, 1993, the cutoff date for the first interim analysis of efficacy, 477 pregnant women were enrolled; during the study period, 409 gave birth to 415 live-born infants. HIV-infection status was known for 363 births (180 in the zidovudine group and 183 in the placebo group). Thirteen infants in the zidovudine group and 40 in the placebo group were HIV-infected. The proportions infected at 18 months, as estimated by the Kaplan-Meier method, were 8.3 percent (95 percent confidence interval, 3.9 to 12.8 percent) in the zidovudine group and 25.5 percent (95 percent confidence interval, 18.4 to 32.5 percent) in the placebo group. This corresponds to a 67.5 percent (95 percent confidence interval, 40.7 to 82.1 percent) relative reduction in the risk of HIV transmission (Z = 4.03, P = 0.00006). Minimal short-term toxic effects were observed. The level of hemoglobin at birth in the infants in the zidovudine group was significantly lower than that in the infants in the placebo group. By 12 weeks of age, hemoglobin values in the two groups were similar.

Conclusions. In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six

Cited by: 1773

This article has been cited 1773 times (from Web of Science).

Ana CP, Ana MAP, Elba WH, et al. Changes in vertically transmitted human immunodeficiency virus infection Chile REVISTA CHILENA DE INFECTOLOGIA 5 368-371 OCT

Robinson JL Testing for HIV infection in pregnancy PAEDIATRICS & CHILD HEALTH 3 221-224 MAR

de Almeida CAF, Benatti MCC Occupational exposure of health care workers to organic fluids and adhesion to chemoprophylaxis REVISTA DA ESCOLA DE ENFERMAGEM DA USP 1 120-126 MAR

view all 1773 citing articles

Create Citation Alert


Related Records:


Find similar records based on shared references (from Web of Science).

[view related records]



Internet









Take the next step 🧷

Search History

Web of Science

Additional Resources

Search Cited Reference Search Structure Search Advanced Search

Web of Science®

<< Back to results list

Record 1 of 1634

Record from Web of Science®

REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT

Print (E-mail) (Add to Marked List) (Save to EndNote Web

Marked List (0)

Author(s): CONNOR EM, SPERLING RS, GELBER R, KISELEV P, SCOTT G, OSULLIVAN MJ, VANDYKE R, BEY M, SHEARER W, JACOBSON RL, JIMENEZ E, ONEILL E, BAZIN B, DELFRAISSY JF, CULNANE M, COOMBS R, ELKINS M, MOYE J, STRATTON P, BALSLEY J

Source: NEW ENGLAND JOURNAL OF MEDICINE Volume: 331 Issue: 18 Pages: 1173-1180 Published: NOV 3 1994

Times Cited: 1.773 References: 39

Abstract: Background and Methods. Maternal-infant transmission is the primary means by which young children become infected with human immunodeficiency virus type 1 (HIV). We conducted a randomized, double-blind, placebo-controlled trial of the efficacy and safety of zidovudine in reducing the risk of maternal-infant HIV transmission. HIV-infected pregnant women (14 to 34 weeks' gestation) with CD4+ T-lymphocyte counts above 200 cells per cubic millimeter who had not received antiretroviral therapy during the current pregnancy were enrolled. The zidovudine regimen included antepartum zidovudine (100 mg orally five times daily), intrapartum zidovudine (2 mg per kilogram of body weight given intravenously over a one-hour period, then 1 mg per kilogram per hour until delivery), and zidovudine for the newborn (2 mg per kilogram orally every six hours for six weeks). Infants with at least one positive HIV culture of peripheral-blood mononuclear cells were classified as HIV-infected.

Results, From April 1991 through December 20, 1993, the cutoff date for the first interim analysis of efficacy, 477 pregnant women were enrolled; during the study period, 409 gave birth to 415 live-born infants. HIV-infection status was known for 363 births (180 in the zidovudine group and 183 in the placebo group). Thirteen infants in the zidovudine group and 40 in the placebo group were HIV-infected. The proportions infected at 18 months, as estimated by the Kaplan-Meier method, were 8.3 percent (95 percent confidence interval, 3.9 to 12.8 percent) in the zidovudine group and 25.5 percent (95 percent confidence interval, 18.4 to 32.5 percent) in the placebo group. This corresponds to a 67.5 percent (95 percent confidence interval, 40.7 to 82.1 percent) relative reduction in the risk of HIV transmission (Z = 4.03, P = 0.00006). Minimal short-term toxic effects were observed. The level of hemoglobin at birth in the infants in the zidovudine group was significantly lower than that in the infants in the placebo group. By 12 weeks of age, hemoglobin values in the two groups were similar.

Conclusions. In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six Cited by: 1773

This article has been cited 1773 times (from Web of Science).

Ana CP, Ana MAP, Elba WH, et al. Changes in vertically transmitted human immunodeficiency virus infection Chile REVISTA CHILENA DE INFECTOLOGIA 5 368-371 OCT

Robinson JL Testing for HIV infection in pregnancy PAEDIATRICS & CHILD HEALTH 3 221-224 MAR

de Almeida CAF, Benatti MCC Occupational exposure of health care workers to organic fluids and adhesion to chemoprophylaxis REVISTA DA ESCOLA DE ENFERMAGEM DA USP 1 120-126 MAR

view all 1773 citing articles

Create Citation Alert

Related Records:


Find similar records based on shared references (from Web of Science).

[view related records]



Internet

100%



Times Cited: 0

more options / values..

Take the next step 🧷

Web of Science

Additional Resources

Search Cited Reference Search Structure Search Advanced Search Search History Marked List (0)

Web of Science®

<< Back to results list

■ Record 1 of 1634 ▶

Record from Web of Science®

REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT

Print (E-mail) (Add to Marked List) (Save to EndNote Web

Author(s): CONNOR EM, SPERLING RS, GELBER R, KISELEV P, SCOTT G, OSULLIVAN MJ, VANDYKE R, BEY M, SHEARER W, JACOBSON RL, JIMENEZ E, ONEILL E, BAZIN B, DELFRAISSY JF, CULNANE M, COOMBS R, ELKINS M, MOYE J, STRATTON P, BALSLEY J

Source: NEW ENGLAND JOURNAL OF MEDICINE Volume: 331 Issue: 18 Pages: 1173-1180 Published: NOV 3 1994

Times Cited: 1.773 References: 39

Abstract: Background and Methods. Maternal-infant transmission is the primary means by which young children become infected with human immunodeficiency virus type 1 (HIV). We conducted a randomized, double-blind, placebo-controlled trial of the efficacy and safety of zidovudine in reducing the risk of maternal-infant HIV transmission. HIV-infected pregnant women (14 to 34 weeks' gestation) with CD4+ T-lymphocyte counts above 200 cells per cubic millimeter who had not received antiretroviral therapy during the current pregnancy were enrolled. The zidovudine regimen included antepartum zidovudine (100 mg orally five times daily), intrapartum zidovudine (2 mg per kilogram of body weight given intravenously over a one-hour period, then 1 mg per kilogram per hour until delivery), and zidovudine for the newborn (2 mg per kilogram orally every six hours for six weeks). Infants with at least one positive HIV culture of peripheral-blood mononuclear cells were classified as HIV-infected.

Results, From April 1991 through December 20, 1993, the cutoff date for the first interim analysis of efficacy, 477 pregnant women were enrolled; during the study period, 409 gave birth to 415 live-born infants. HIV-infection status was known for 363 births (180 in the zidovudine group and 183 in the placebo group). Thirteen infants in the zidovudine group and 40 in the placebo group were HIV-infected. The proportions infected at 18 months, as estimated by the Kaplan-Meier method, were 8.3 percent (95 percent confidence interval, 3.9 to 12.8 percent) in the zidovudine group and 25.5 percent (95 percent confidence interval, 18.4 to 32.5 percent) in the placebo group. This corresponds to a 67.5 percent (95 percent confidence interval, 40.7 to 82.1 percent) relative reduction in the risk of HIV transmission (Z = 4.03, P = 0.00006). Minimal short-term toxic effects were observed. The level of hemoglobin at birth in the infants in the zidovudine group was significantly lower than that in the infants in the placebo group. By 12 weeks of age, hemoglobin values in the two groups were similar.

Conclusions. In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six

Cited by: 1773

This article has been cited 1773 times (from Web of Science).

Ana CP, Ana MAP, Elba WH, et al. Changes in vertically transmitted human immunodeficiency virus infection Chile REVISTA CHILENA DE INFECTOLOGIA 5 368-371 OCT

Robinson JL Testing for HIV infection in pregnancy PAEDIATRICS & CHILD HEALTH 3 221-224 MAR

de Almeida CAF, Benatti MCC Occupational exposure of health care workers to organic fluids and adhesion to chemoprophylaxis REVISTA DA ESCOLA DE ENFERMAGEM DA USP 1 120-126 MAR

view all 1773 citing articles

Create Citation Alert

Related Records:


Find similar records based on shared references (from Web of Science).


[view related records]



Internet

100%





REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT

Print E-mail Add to Marked List Save to EndNote Web

Author(s): CONNOR EM. SPERLING RS. GELBER R. KISELEV P. SCOTT G. OSULLIVAN MJ. VANDYKE R. BEY M. SHEARER W. JACOBSON RL, JIMENEZ E, ONEILL E, BAZIN B, DELFRAISSY JF, CULNANE M, COOMBS R, ELKINS M, MOYE J, STRATTON P. BALSLEYJ

Source: NEW ENGLAND JOURNAL OF MEDICINE Volume: 331 Issue: 18 Pages: 1173-1180 Published: NOV 3 1994

Times Cited: 1.773 References: 39

Abstract: Background and Methods. Maternal-infant transmission is the primary means by which young children become infected with human immunodeficiency virus type 1 (HIV). We conducted a randomized, double-blind, placebo-controlled trial of the efficacy and safety of zidovudine in reducing the risk of maternal-infant HIV transmission. HIV-infected pregnant women (14 to 34 weeks' gestation) with CD4+ T-lymphocyte counts above 200 cells per cubic millimeter who had not received antiretroviral therapy during the current pregnancy were enrolled. The zidovudine regimen included antepartum zidovudine (100 mg orally five times daily), intrapartum zidovudine (2 mg per kilogram of body weight given intravenously over a one-hour period, then 1 mg per kilogram per hour until delivery), and zidovudine for the newborn (2 mg per kilogram orally every six hours for six weeks). Infants with at least one positive HIV culture of peripheral-blood mononuclear cells were classified as HIV-infected.

Results, From April 1991 through December 20, 1993, the cutoff date for the first interim analysis of efficacy, 477 pregnant women were enrolled; during the study period, 409 gave birth to 415 live-born infants, HIV-infection status was known for 363 births (180 in the zidovudine group and 183 in the placebo group). Thirteen infants in the zidovudine group and 40 in the placebo group were HIV-infected. The proportions infected at 18 months, as estimated by the Kaplan-Meier method, were 8.3 percent (95 percent confidence interval, 3.9 to 12.8 percent) in the zidovudine group and 25.5 percent (95 percent confidence interval, 18.4 to 32.5 percent) in the placebo group. This corresponds to a 67.5 percent (95 percent confidence interval, 40.7 to 82.1 percent) relative reduction in the risk of HIV transmission (Z = 4.03, P = 0.00006). Minimal short-term toxic effects were observed. The level of hemoglobin at birth in the infants in the zidovudine group was significantly lower than that in the infants in the placebo group. By 12 weeks of age, hemoglobin values in the two groups were similar.

Conclusions. In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six weeks reduced the risk of maternal-infant HIV transmission by approximately two thirds.

Document Type: Article

Language: English

KevWords Plus: CLINICAL-TRIALS GROUP: RETROVIRAL DISEASE: HIV-1 INFECTION: PREGNANCY: VIREMIA: EMBRYOS: THERAPY; 3'-AZIDO-3'-DEOXYTHYMIDINE; PHARMACOKINETICS; PREIMPLANTATION

Addresses: UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT PEDIAT, NEWARK, NJ 07103 USA CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA HARVARD UNIV, SCH PUBL HLTH, AIDS CLIN TRIALS GRP, CTR STAT & DATA ANAL, BOSTON, MA 02115 USA DANA FARBER CANC INST. BOSTON, MA USA UNIV MIAMI, SCH MED, DEPT PEDIAT, MIAMI, FL USA

Cited by: 1773

This article has been cited 1773 times (from Web of Science).

Ana CP, Ana MAP, Elba WH, et al. Changes in vertically transmitted human immunodeficiency virus infection Chile REVISTA CHILENA DE INFECTOLOGIA 5 368-371 OCT

Robinson JL Testing for HIV infection in pregnancy PAEDIATRICS & CHILD HEALTH 3 221-224 MAR

de Almeida CAF, Benatti MCC Occupational exposure of health care workers to organic fluids and adhesion to chemoprophylaxis REVISTA DA ESCOLA DE ENFERMAGEM DA USP 1 120-126 MAR

view all 1773 citing articles

Create Citation Alert

Related Records:

Find similar records based on shared references (from web of Science


[view related records]

References: 39

View the bibliography of this record (from Web of Science).


Suggest a correction

If you would like to improve the quality of this product by suggesting corrections, please fill out this form.









Current Limits: [Hide Limits and Settings] (To save these permanently, sign in or register.)

Timespan:




Citation Databases:

Science Citation Index Expanded (SCI-EXPANDED)--1990-2008

Chemical Databases:

- Index Chemicus (IC)--1993-2008
- Current Chemical Reactions (CCR-EXPANDED [back to 1840])--1986-2008

Restrict results by any or all of the options below:





Search History

Search



Analyze Results & Citation Report






Sign In | My Endnote Web | My Citation Alerts | My Saved Searches | Log Out | Help

ISI Web of Knowledge™





Please give us your feedback on using ISI Web of Knowledge.

Acceptable Use Policy Copyright @ 2008 The Thomson Corporation

THOMSON

Analyze

Analyze Results

1,634 records. Topic=(hiv children treatment)

Rank the records by this field:	Analyze:	Set display options:	Sort by:
Author Country/Territory Document Type Institution Name	Up to 2500 records.	Show the top 10 results. Minimum record count (threshold): 2	Record count Selected field

Use the checkboxes below to view the records. You can choose to view those selected records, or you can exclude them (and view the others). Note: The number of records displayed may be greater than the listed Record Count if the original set contained more records than the number of records analyzed

View Records X Exclude Records	Field: Author	Record Count	% of 1634	Bar Chart	Save Analysis Data to File			
	BLANCHE, S	29	1.7748 %	1				
	NEWELL, ML	28	1.7136 %	1				
	GIBB, DM	25	1.5300 %	1				
	SPECTOR, SA	25	1.5300 %	1				
	YOGEV, R	24	1.4688 %	1				
	WIZNIA, A	23	1.4076 %	1				
	GIAQUINTO, C	22	1.3464 %	1				
	ROUZIOUX, C	21	1.2852 %	1				
	MCINTOSH, K	20	1.2240 %	1				
	GALLI, L	19	1.1628 %	1				
View Records X Exclude Records	Field: Author	Record Count	% of 1634	Bar Chart	Save Analysis Data to File			
(67	(6741 Author value(s) outside display options.)							

Analyze

Analyze Results


1,634 records. Topic=(hiv children treatment)


Rank the records by this field:	Analyze:	Set display options:	Sort by:
Author Country/Territory Document Type Institution Name	Up to 2500 records.	Show the top 10 results. Minimum record count (threshold): 2	Record count Selected field


Use the checkboxes below to view the records. You can choose to view those selected records, or you can exclude them (and view the others). Note: The number of records displayed may be greater than the listed Record Count if the original set contained more records than the number of records analyzed.


View Records X Exclude Records	Field: Author	Record Count	% of 1634	Bar Chart	Save Analysis Data to File
\longrightarrow	BLANCHE, S	29	1.7748 %	1	
	NEWELL, ML	28	1.7136 %	1	
\longrightarrow	GIBB, DM	25	1.5300 %	1	
	SPECTOR, SA	25	1.5300 %	1	
	YOGEV, R	24	1.4688 %	1	
	WIZNIA, A	23	1.4076 %	1	
	GIAQUINTO, C	22	1.3464 %	1	
	ROUZIOUX, C	21	1.2852 %	1	
	MCINTOSH, K	20	1.2240 %	1	
	GALLI, L	19	1.1628 %	1	
View Records X Exclude Records	Field: Author	Record Count	% of 1634	Bar Chart	Save Analysis Data to File


(6741 Author value(s) outside display options.)


















Results	: 1634					Sort by:	Times	Cited
	Use the checkboxes to remove individual items from this Citation Report	2004	2005	2006	2007	2008	Total	Average Citations per Year
<u>.</u>	or restrict to items processed between 1986 🕶 and 2008 💌 🙃	1862	2385	2439	2938	1286	23,132	1285.11
□ 1.	Title: REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT Author(s): CONNOR EM, SPERLING RS, GELBER R, et al. Source: NEW ENGLAND JOURNAL OF MEDICINE Volume: 331 Issue: 18 Pages: 1173-1180 Published: NOV 3 1994	76	94	80	98	28	1,773	118.20
□ 2.	Title: Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients Author(s): Lennette ET, Blackbourn DJ, Levy JA Source: LANCET Volume: 348 Issue: 9031 Pages: 858-861 Published: SEP 28 1996	8	21	15	9	1	387	29.77
3.	Title: 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial Author(s): Dabis F, Msellati P, Meda N, et al. Source: LANCET Volume: 353 Issue: 9155 Pages: 786-792 Published: MAR 6 1999	22	22	21	17	8	287	28.70
4.	Title: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues Author(s): Blanche S, Tardieu M, Rustin P, et al. Source: LANCET Volume: 354 Issue: 9184 Pages: 1084-1089 Published: SEP 25 1999	29	24	17	21	5	269	26.90
☐ 5.	Title: Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 Author(s): Ormerod P, Campbell I, Novelli V, et al. Source: THORAX Volume: 53 Issue: 7 Pages: 536-548 Published: JUL 1998	20	38	29	18	9	232	21.09
□ 6.	Title: PNEUMOCOCCAL DISEASE DURING HIV-INFECTION - EPIDEMIOLOGIC, CLINICAL, AND IMMUNOLOGICAL PERSPECTIVES Author(s): JANOFF EN, BREIMAN RF, DALEY CL, et al. Source: ANNALS OF INTERNAL MEDICINE Volume: 117 Issue: 4 Pages: 314-324 Published: AUG 15 1992	5	6	5	5	5	219	12.88
7.	Title: ZIDOVUDINE RESISTANCE AND HIV-1 DISEASE PROGRESSION DURING ANTIRETROVIRAL THERAPY Author(s): DAQUILA RT, JOHNSON VA, WELLES SL, et al. Source: ANNALS OF INTERNAL MEDICINE Volume: 122 Issue: 6 Pages: 401-408 Published: MAR 15 1995	8	12	0	5	0	214	15.29

Ва	SI Web of Knowledge Page 7 (Articles 01 - 70) 1 2 3 4 5 6 7] ▶							Print This Page	
		2004	2005	2006	2007	2008	Total	Average Citations per Year	
		1862	2385	2439	2938	1286	23,132	1285.11	
61.	Author(s): Mueller, BU; NElson, RP; Sleasman, J; et al. Title: A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection Source: PEDIATRICS, 101 (3): 335-343 MAR 1998 ISSN: 0031-4005	4	4	2	2	0	62	5.64	
62.	Author(s): DOMANSKI, MJ; SLOAS, MM; FOLLMANN, DA; et al. Title: EFFECT OF ZIDOVUDINE AND DIDANOSINE TREATMENT ON HEART FUNCTION IN CHILDREN INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS Source: JOURNAL OF PEDIATRICS, 127 (1): 137-146 JUL 1995 ISSN: 0022-3476	5	2	1	1	1	61	4.36	
63.	Author(s): MUSTAFA, MM; WEITMAN, SD; WINICK, NJ; et al. Title: SUBACUTE MEASLES ENCEPHALITIS IN THE YOUNG IMMUNOCOMPROMISED HOST - REPORT OF 2 CASES DIAGNOSED BY POLYMERASE CHAIN-REACTION AND TREATED WITH RIBAVIRIN AND REVIEW OF THE LITERATURE Source: CLINICAL INFECTIOUS DISEASES, 16 (5): 654-660 MAY 1993 ISSN: 1058-4838	5	1	4	1	1	60	3.75	
64.	Author(s): Michalets, EL; Williams, CR Title: Drug interactions with cisapride - Clinical implications Source: CLINICAL PHARMACOKINETICS, 39 (1): 49-75 JUL 2000 ISSN: 0312-5963	10	9	3	9	1	59	6.56	
65.	Author(s): Moye, J; Rich, KC; Kalish, LA; et al. Title: Natural history of somatic growth in infants born to women infected by human immunodeficiency virus Source: JOURNAL OF PEDIATRICS, 128 (1): 58-69 JAN 1996 ISSN: 0022-3476	3	5	1	1	0	59	4.54	
66.	Author(s): Aarnoutse, RE; Schapiro, JM; Boucher, CAB; et al. Title: Therapeutic drug monitoring - An aid to optimising response to antiretroviral drugs? Source: DRUGS, 63 (8): 741-753 2003 ISSN: 0012-6667	11	18	15	10	2	58	9.67	
67.	Author(s): Amadi, B; Mwiya, M; Musuku, J; et al. Title: Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial Source: LANCET, 360 (9343): 1375-1380 NOV 2 2002	10	16	11	10	3	58	8.29	
Done				•	Interne	t		₫ 100% 🕶	

















Refine



Web of Science Marked Records	s - 4 Articles			
Scroll down to view records				elete This List
Step 1. Select the fields to include	in the output. Reset to Defaults			
✓ Author(s)	✓ Title	✓ Source	abstract*	
☐ language	document type	keywords	addresses	
cited references*	cited reference count	times cited	publisher information	
✓ ISSN	source abbrev.	page count	□ IDS number	
subject category	ncrease the processing time.			
Selecting these items will h	ricrease the processing time.			
Step 2. Select an option. Field Tagged	Format for Print Save to My EndNote Web	E-mail records to:		
	Save to EndNote, RefMan, ProCite	Return e-mail (optional):		
		Notes (optional):		
Other Reference Software				
Other Reference Software		Plain Text 💌	E-mail	
		Plain Text 💌	E-mail	
	Save to File	Plain Text 💌	E-mail	







More information Mashad University of Medical Sciences

Discover Web of Science

Explore top high-impact journals with powerful tools such as cited reference searching and Author Finder, 256 categories thoroughly cover the sciences, social sciences, arts, and humanities,

- Want to know more?
- Training in multiple languages

Customize Your Experience

Sign In | Register

- Save and manage your references online with EndNote Web - freely available and fully integrated.
- Save and run searches
- Create alerts and RSS feeds
- Choose your start page
- Want to know more?

My ResearcherID

- What is ResearcherID?
- Sign In to ISI Web of Knowledge to get your ResearcherID.


Further Information

- What's New?
- Training and Support
- Help Desk
- Provide Feedback
- Search the Web with Thomson Scientific WebPlus



100%

Take the next step 🧷



More information for new users Mashad University of Medical Sciences

Discover Web of Science

Explore top high-impact journals with powerful tools such as cited reference searching and Author Finder, 256 categories thoroughly cover the sciences, social sciences, arts, and humanities.

- Want to know more?
- Training in multiple languages

Customize Your Experience

Sign In | Register

- Save and manage your references online with EndNote Web - freely available and fully integrated.
- Save and run searches
- Create alerts and RSS feeds
- Choose your start page
- Want to know more?

My ResearcherID


- What is ResearcherID?
- Sign In to ISI Web of Knowledge to get your ResearcherID.

Further Information


- What's New?
- Training and Support
- Help Desk
- Provide Feedback
- Search the Web with Thomson



Scientific WebPlus







Take the next step 🗷

Web of Science

Additional Resources

Search Cited Reference Search Structure Search

Advanced Search Search History

Marked List (0)

Web of Science®


<< Back to previous results list


Citation Report Author=(balali)

Timespan=All Years. Databases=SCI-EXPANDED, IC, CCR-EXPANDED [back to 1840].

This report reflects citations to source items indexed within Web of Science. Perform a Cited Reference Search to include citations to items not indexed within Web of Science.

Published Items in Each Year







Results: 36

► Page 1

of 4 Go >>

Sort by: Times Cited

Average Citations per Year

10.92

3.64

Use the checkboxes to remove individual items from this Citation Report or restrict to items processed between 1986 | and 2008 | Go

Title: Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes

Author(s): Balali-Mood M. Shariat M.

Source: JOURNAL OF PHYSIOLOGY-PARIS Volume: 92 Issue: 5-6 Pages: 375-378 Published: OCT-DEC 1998


Internet

2005 2006 2007 2008 Total

100%

Results: 36 Page 1 of 4 Go ▶▶					Sort by: Times Cited						
	Use the checkboxes to remove individual items from this Citation Report	2004	2005	2006	2007	2008	Total	Average Citations per Year			
÷	or restrict to items processed between 1986 and 2008 Go	10	18	24	40	31	142	10.92			
1.	Title: Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes Author(s): Balali-Mood M, Shariat M Source: JOURNAL OF PHYSIOLOGY-PARIS Volume: 92 Issue: 5-6 Pages: 375-378 Published: OCT-DEC 1998	7	6	7	6	6	40	3.64			
2 .	Title: DNA fingerprinting probe specific to isolates of Rhizoctonia solani AG-3 Author(s): Balali GR, Whisson DL, Scott ES, et al. Source: MYCOLOGICAL RESEARCH Volume: 100 Pages: 467-470 Part: Part 4 Published: APR 1996	1	0	0	2	0	11	0.85			
3.	Title: Neutron diffraction reveals sequence-specific membrane insertion of pre-fibrillar islet amyloid polypeptide and inhibition by rifampicin Author(s): Balali-Mood K, Ashley RH, Hauss T, et al. Source: FEBS LETTERS Volume: 579 Issue: 5 Pages: 1143-1148 Published: FEB 14 2005	0	1	2	3	3	9	2.25			
4.	Title: Molecular dynamics simulations of a mixed DOPC/DOPG bilayer Author(s): Balali-Mood K, Harroun TA, Bradshaw JP Source: EUROPEAN PHYSICAL JOURNAL E Volume: 12 Pages: \$135-\$140 Supplement: Suppl. 1 Published: NOV 2003	1	3	2	2	0	8	1.33			
5.	Title: Anastomosis group and pathogenicity of isolates of Rhizoctoniasolani from potato crops in South Australia Author(s): Balali GR, Neate SM, Scott ES, et al. Source: PLANT PATHOLOGY Volume: 44 Issue: 6 Pages: 1050-1057 Published: DEC 1995	1	0	0	2	2	8	0.62			
6.	Title: The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning Author(s): Balali-Mood M, Hefazi M Source: FUNDAMENTAL & CLINICAL PHARMACOLOGY Volume: 19 Issue: 3 Pages: 297-315 Published: JUN 2005	0	0	0	6	1	7	1.75			
7.	Title: Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans Author(s): Balali-Mood M, Hefazi M, Mahmoudi M, et al. Source: FUNDAMENTAL & CLINICAL PHARMACOLOGY Volume: 19 Issue: 6 Pages: 713-721 Published: DEC 2005	0	0	1	5	0	6	1.50			

Take the next step 🧷



More information Mashad University of Medical Sciences

Discover Web of Science

Explore top high-impact journals with powerful tools such as cited reference searching and Author Finder. 256 categories thoroughly cover the sciences, social sciences, arts, and humanities,

- Want to know more?
- Training in multiple languages

Customize Your Experience

Sign In | Register

- Save and manage your references online with EndNote Web - freely available and fully integrated.
- Save and run searches
- Create alerts and RSS feeds
- Choose your start page
- Want to know more?

My ResearcherID


- What is ResearcherID?
- Sign In to ISI Web of Knowledge to get your ResearcherID.


Further Information

- What's New?
- Training and Support
- Help Desk
- Provide Feedback
- Search the Web with Thomson Scientific WebPlus



100%







Please give us your feedback on using Author Finder.


Acceptable Use Policy
Copyright © 2007 The Thomson Corporation

THOMSON

🔼 Done








Please give us your feedback on using Author Finder.

Acceptable Use Policy Copyright © 2007 The Thomson Corporation

Sign In | My Endnote Web | My Citation Alerts | My Saved Searches | Log Out | Help

ISI Web of Knowledge™






Please give us your feedback on using Author Finder.

Acceptable Use Policy
Copyright © 2007 The Thomson Corporation







Search Cited Reference Search

Structure Search Search History Marked List (0) Advanced Search

options

Web of Science®

Results Subject Heading=(LIFE SCIENCES BIOMEDICINE OR MULTIDISCIPLINARY SCIENCE TECHNOLOGY OR PHYSICAL SCIENCES) AND Author=(BALALI M*) AND Institution=(MASHHAD UNIV MED SCI OR UNIV EDINBURGH OR CNR OR UNIV OXFORD OR GHAEM HOSP OR GLAXOSMITHKLINE OR MASHHAD SCH MED OR TEHRAN UNIV MED SCI OR AL ZAHRA HOSP OR BIOTECHNOL RES CTR OR BU ALI RES INST OR HAHN MEITNER INST BERLIN GMBH OR IMAM REZA HOSP OR ISFAHAN UNIV MED SCI OR KHATAMOLANBYA HOSP OR MASHAD UNIV MED SCI OR NATL RES COUNCIL CANADA OR UNIV LONDON UNIV COLL) Timespan=All Years. Databases=IC, SCI-EXPANDED, CCR-EXPANDED [back to 1840].

E-mail Add to Marked List Save to EndNote Web more

Results: 28

✓ Page 1



Sort by: Latest Date

Analyze Results Create Citation Report

Refine Results

Search within results for

Search

Refine

Refine

Subject Areas TOXICOLOGY (7)

- PHARMACOLOGY & PHARMACY (6) BIOCHEMISTRY & MOLECULAR
- BIOLOGY (5)
- BIOPHYSICS (5)
- CELL BIOLOGY (2) more options / values ...

Document Types

ARTICLE (18)

- MEETING ABSTRACT (5)
- REVIEW (3)
- LETTER (2)
- more options / values...
- Authors
- Source Titles


- 1. Title: Impact of scientific developments on the chemical weapons convention (IUPAC technical report)
 - Author(s): Balali-Mood M, Stevn PS, Sydnes LK, et al. Source: PURE AND APPLIED CHEMISTRY Volume: 80 Issue: 1 Pages: 175-200 Published: JAN 2008 Times Cited: 1
- 2. Title: Blood lead concentrations in one- to seven-year-old children in Mashhad, Iran Author(s): Shah-Farhat A, Khademy GR, Balali-Mood M Source: CLINICAL TOXICOLOGY Volume: 45 Issue: 7 Pages: 812-813 Published: OCT-NOV 2007 Times Cited: 0
- 3. Title: Comparison of blood lead levels of mothers and cord blood in intrauterine growth retarded neonates and normal term neonates


Author(s): Iranpour R, Besharati AA, Nasseri F, et al.


- Source: SAUDI MEDICAL JOURNAL Volume: 28 Issue: 6 Pages: 877-880 Published: JUN 2007 Times Cited: 0
- 4. Title: Multi-scale simulations of membrane bound monotopic proteins Author(s): Balali-Mood K
 - Source: BIOPHYSICAL JOURNAL Pages: 557A-558A Supplement: Suppl. S Published: JAN 2007 Times Cited: 0
- 5. Title: Monotopic enzymes and lipid bilayers: A comparative study Author(s): Fowler PW, Balali-Mood K, Deol S, et al.
 - Source: BIOCHEMISTRY Volume: 46 Issue: 11 Pages: 3108-3115 Published: MAR 20 2007

Times Cited: 1









Internet

Print Option

